Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Feray, M. Gigou, D. Samuel, et al.
The course of hepatitis C infection after liver transplantation.
Hepatology, 20 (1994), pp. 1137-1143
[2.]
C. Feray, L. Caccamo, G.J. Alexander, et al.
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C.
Gastroenterology, 117 (1999), pp. 619-625
[3.]
D. Samuel, C. Feray.
Recurrence of hepatitis C virus infection after liver transplantation.
J Hepatol, 31 (1999), pp. 217-221
[4.]
E.J. Gane, Naoumov NV., K.P. Qian, et al.
A longitudinal analysis of hepatitis C virus replication following liver transplantation.
Gastroenterology, 110 (1996), pp. 167-177
[5.]
E.J. Gane, B.C. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, P.T. Donaldson, et al.
Long-term outcome of hepatitis C infection after liver transplantation.
N Engl J Med, 334 (1996), pp. 815-820
[6.]
H.R. Rosen, D.R. Gretch, M. Oehlke, et al.
Timing and severity of initial hepatitis C recurrence aas predictors of long term liver allograft injury.
Transplantation, 65 (1998), pp. 1178-1182
[7.]
M. Prieto, M. Berenguer, J.M. Rayon, et al.
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation. Relationship with rejection episodes.
Hepatology, 29 (1999), pp. 250-256
[8.]
G. Szabo, E. Katz, H.L. Bonkovsky.
Management of recurrent hepatitis C after liver transplantation: a concise review.
Am J Gastroenterol, 95 (2000), pp. 2164-2170
[9.]
T.L. Wright, C. Combs, M. Kim, et al.
Interferon alpha therapy for hepatitis C virus infectionfollowing liver transplantation.
Hepatology, 20 (1994), pp. 773-779
[10.]
C. Feray, D. Samuel, M. Gigou, et al.
An open trial of interferon α recombinant for hepatitis C after liver transplantation antiviral: antiviral effects and risk of rejection.
Hepatology, 22 (1995), pp. 1084-1089
[11.]
E.J. Gane, C.J. Tibbs, J.K. Ramage, et al.
Ribavirin therapy for hepatitis C infection following liver transplantation.
Transpl Int, 8 (1995), pp. 61-64
[12.]
T. Bizollon, U. Palazzo, C. Ducerf, M. Chevallier, M. Elliott, J. Baulieux, et al.
Pilot study of the combination of interferon α and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Hepatology, 26 (1997), pp. 500-504
[13.]
G.T. Everson, T. Trouillot, J. Trotter, et al.
Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferon-α-2b plus ribavirin: safety and efficacy [abstract].
Hepatology, 32 (2000), pp. 595
[14.]
J.S. Crippin, P. Sheiner, T. Terrault, et al.
A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C [abstract].
Hepatology, 32 (2000), pp. 594
[15.]
P. Sheiner, P. Boros, F.M. Klion, et al.
The efficacy of prophylactic interferon α-2b in preventing recurrent hepatitis C after liver transplantation.
Hepatology, 28 (1998), pp. 831-838
[16.]
C. Manzarbeitia, L. Tepermann, N. Chalasani, et al.
40KDA Peginterferon α-2 a (Pegasys) as a prophylaxis against Hepatitis C infection recurrence after liver transplantation: preliminary results of a randomized multicenter trial. [abstract].
Hepatology, 34 (2001), pp. 938
[17.]
P. Ferenci, M. Peck-Radosavljevic, W. Vogel, et al.
40 KDA Peginterferon α-2 a (Pegasys)in post-Liver Transplant recipients with established recurrent Hepatitis C: preliminary results of a randomized multicenter trial [abstract].
Hepatology, 34 (2001), pp. 937
[18.]
S. Coritori, J.Y. Lau, Ch-Ch. Lin.
Safety studies of Levovirin, a second generation Ribavirin candidate,showed excellent safety profile [abstract].
Hepatology, 34 (2001), pp. 181
[19.]
Ch-Ch Lin, K. Luu, D. Lourenco, et al.
Comparative absorption, metabolism and excretion studies of Ribavirin versus Viramidine, a liver-targeted Ribavirin pro-drug [abstract].
Hepatology, 34 (2001), pp. 182
[20.]
M. Berenguer, F.X. Lopez-Labrador, T.L. Wright.
Hepatitis C and liver transplantation.
J Hepatol, 35 (2001), pp. 666-678
[21.]
B. Rehermann.
Immunology of Hepatitis C en: update on viral hepatitis. Postgraduate Course 2000.
pp. p119-p126
[22.]
H.R. Rosen, D.J. Hinrichs, D.R. Gretch, et al.
Association of multispecific CD4+ response to hepatitis C severity recurrence after liver transplantation.
Gastroenterology, 117 (1999), pp. 926-932
[23.]
S.M. Kamal, L. Bianchi, A. Al Tawil, et al.
Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni.
JID, 184 (2001), pp. 972-982
[24.]
J.H. Hoofnagle.
Therapy for acute Hepatitis C.
N Engl J Med, 345 (2001), pp. 1495-1497
[25.]
E. Jaeckel, M. Cornberg, H. Wedemeyer, et al.
German acute hepatitis C therapy group.
N Engl J Med, 345 (2001), pp. 1452-1457
[26.]
J.F. Pawlotsky, M. Bouvier-Alias, C. Hezode, et al.
Standardization of hepatitis C virus RNA quantification.
Hepatology, 32 (2000), pp. 654-659
[27.]
F.C. Bekkering, J.T. Brouwer, B.E. Hansen, et al.
Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.
J Hepatol, 34 (2001), pp. 435-440
[28.]
T. Poynard, J. McHutchinson, Goodmanz, et al.
Is an «a la carte» combination interferon α-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
Hepatology, 31 (2000), pp. 211-218
[29.]
J. Heathcote, M.L. Shiffman, G.E. Cooksley, et al.
Peginterferon α-2 a in patients with chronic hepatitis C and cirrhosis.
N Engl Med, 343 (2000), pp. 1673-1680
[30.]
S. Zeuzem, S.V. Feinman, J. Rasenack, et al.
Peginterferon α-2 a in patients with chronic hepatitis C.
N Engl Med, 343 (2000), pp. 1666-1672
[31.]
M.W. Fried, M.L. Shiffman, R.K. Reddy, et al.
Pegylated (40 KDa) interferon α-2 a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III randomized, actively controlled multicenter study [abstract].
Gastroenterology, 120 (2001), pp. 55
[32.]
M. Manns, J.G. McHutchinson, S.S. Gordon, et al.
Peginterferon α-2 b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.
Lancet, 358 (2001), pp. 958-965
[33.]
S. Brillanti, F. Levantesi, L. Masi, et al.
Triple antiviral therpay as a new option for patients with inerferon non response chronic hepatitis C.
Hepatology, 32 (2000), pp. 630-634
[34.]
M.L. Shiffman.
Improvement in liver histopathology associated with interferon therapy in patients with chronic hepatitis C.
Viral Hepatitis Reviews, 5 (1999), pp. 27-43
[35.]
Y. Shiratori, F. Imazeki, M. Moriyama, et al.
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.
Ann Intern Med, 132 (2000), pp. 517-524
[36.]
J.H. Hoofnagle, K.D. Mullen, D.B. Jones, et al.
Treatment of chronic non-A non-Blahepatitis with recombinant human alpha interferon.
N Engl Med, 315 (1986), pp. 1575-1578
[37.]
J.M. Pawlotsky.
Hepatitis C virus resistance to antiviral therapy.
Hepatology, 32 (2000), pp. 889-896
[38.]
J.M. Pawlotsky, A.U. Neumann, H. Dahari, et al.
Hepatitis C virus (HCV) dynamics during induction therapy with interferon (IFN) alpha and/or ribavirin.
Antiviral Ther, 5 (2000), pp. 71
[39.]
M.L. Shiffman, C.h.M. Hofmann, M.J. Contos, et al.
A randomized trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
Gastroenterology, 117 (1999), pp. 1164-1172
[40.]
V. Soriano, J. Garcia-Samaniego.
Management of HIV/HCV coinfection.
Therapy in Hepatology, pp. p291-p299
[41.]
M. Berenguer, F.X. Lopez-Labrador, H.B. Greenberg, T.L. Wright.
Hepatitis C virus and the host an imbalance induced by immunosuppression.
Hepatology, 32 (2000), pp. 433-435
[42.]
H.R. Rosen, J.J. Lentz, S.L. Rose, et al.
Donor polymorphism of tumor necrosis factor gene.
Transplantation, 68 (1999), pp. 1898-1902
[43.]
G. Gotz, M. Schon, A. Hereafter, R. Neuhaus, T. Berg, U. Hopf, et al.
Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
Tranplant Proc, 30 (1998), pp. 2104-2106
[44.]
L. Fischer, M. Sterneck, C. Valentin-Gamazo, et al.
Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha.
Transplant Proc, 31 (1999), pp. 494-495
[45.]
S.J. Cotler, D.R. Ganger, S. Kaur, et al.
Daily interferon therapy for hepatitis C virus infection in liver transplant recipients.
Transplantation, 71 (2001), pp. 261-266
[47.]
O. Millan, M. Brunet, J. Martorel.
Farmacodinamica dels immunosupressors.
Transplantament. Societat Catalana de Transplantaments. OCATT. Barcelona: ICS Butlleti, 17 (2001), pp. p10-p11
[48.]
F. Casafont.
Inmunosupresion de mantenimiento en el trasplante hepatico. Aula sobre trasplantes de organos solidos.
pp. 135
[49.]
Z. Ben-Ari, O. Papo, J. Sulkes.
Role of mycophenolate moetil in recurrent hepatitis C virus infection after liver transplantation [abstract].
Hepatology, 34 (2001), pp. 952
[50.]
L. Rostaing, J. Izopet, K. Sandres, et al.
Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil.
Transplantation, 69 (2000), pp. 991-994
[51.]
R.M. Ghobrial, D.G. Farmer, A. Baquerizo, S. Colquhoun, H.R. Rosen, H. Yersiz, et al.
Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.
Ann Surg, 229 (1999), pp. 824-833
[52.]
A. Zamauskaite, S. Cohen, P. Sweny.
FK506 and CsA differin their effect on intracellular cytokine expression following kidney transplantation.
Transplant Proc, 33 (2001), pp. 1046-1047
[53.]
G.V. Papatheoridis, D. Patch, G.M. Dusheiko.
The outcome of hepatitis C virus infection after liver transplantation-is it influenced by the type of immunosuppresion?.
J Hepatol, 30 (1999), pp. 731-738
[54.]
A.B. Alberti, L.S. Belli, A. Airoldi, et al.
Combined therapy with Interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
Liver Transplantation, 7 (2001), pp. 870-876
[55.]
M. Castella, G. Tenderich, M.M. Koerner.
Outcome of heart transplantation in patients previously infected with hepatitis C virus.
J Heart Lung Transplant, 20 (2001), pp. 595-598
[56.]
J.K. Delladetsima, F. Makris, M. Psichogiou, et al.
Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection.
Liver, 21 (2001), pp. 81-88
[57.]
M.E. De Vera, G.A. Smallwood, K. Rosado, L. Davis, E. Martinez, S. Sharma, et al.
Interferon-α and ribavirin for the treatment of recurrent hepatitis C after liver transplantation.
Transplantation, 71 (2001), pp. 678-686
[58.]
T. Casanovas, E. Ramos, T. Serrano, et al.
Pilot study with the combination of interferon α and ribavirin for recurrent post-liver transplantation hepatitis C. Causesbof treatment failure in two different populations [abstract].
Hepatology, 34 (2001), pp. 477
[59.]
G. Bellati, A.B. Alberti, L.S. Belli, C. Vai, A. Airoldi, G.F. Rondinara, et al.
Therapy of chronic hepatitis C after liver transplantation: multicenter italian experience.
J Hepatol, 30 (1999), pp. 51
[60.]
D. Samuel.
Combination of Interferon α 2-B plus Ribavirin for recurrent HCV infection after liver transplantation: a randomized controlled study [abstract].
Hepatology, 32 (2000), pp. 295
[61.]
S. Zeuzem.
Clinical implications of Hepatitis C viral kinetics.
J Hepatol, 31 (1999), pp. 61-64
[62.]
Ciclosporina. Aplicacion clinica en las enfermedades autoinmunes.
[63.]
S.J. Cotler, T.E. Wiley, T.J. Layden, et al.
A pilot study of the combination of cyclosporine A and Interferon αcon-1 for the treatment of hepatitis C in previous non-responder patients [abstract].
Hepatology, 34 (2001), pp. 1659
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
